<DOC>
	<DOCNO>NCT02805205</DOCNO>
	<brief_summary>The purpose study estimate efficacy safety PEG-rhG-CSF patient breast cancer receive chemotherapy .</brief_summary>
	<brief_title>PEG-rhG-CSF Patients With Breast Cancer Receiving Chemotherapy Prevent Neutropenia</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Patients age 18 70 year diagnosis breast cancer patient need receive multicycle chemotherapy grade III/IV neutropenia chemotherapy KPS scoreâ‰¥70 life expectancy least 3 month Written inform consent acquire Have accept drug relate clinical trial within 4 week anticipate uncontrolled infection pregnancy Other situation investigator consider contraindication study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>PEG-rhG-CSF neutropenia</keyword>
</DOC>